The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer
Open accessAbstract
Epidemiologic and experimental data support a role for 1,25-dihydroxyvitamin D(3) in the growth regulation of prostate cancer. We conducted a phase II clinical trial evaluating calcitriol (1,25(OH)(2)D(3)) in patients with hormone refractory prostate cancer. We enrolled 14 patients in this study. 1,25(OH)(2)D(3) was initiated at a daily oral dose of 0.5 μg and escalated to 1.5 μg daily. No objective responses were observed. However, in two patients decreases of 25% and 45% in prostate specific antigen levels were seen. Hypercalcemia was the predominant toxicity. We conclude that 1,25(OH)(2)D(3) given in this manner is inactive in advanced prostate cancer. Dose escalation of oral 1,25(OH)(2)D(3) is limited by hypercalcemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Optimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636
Cited by
Epidemiology of Prostate Cancer
Rawla, P. (2019) · World Journal of Oncology · doi:10.14740/wjon1191 · Cited by 2,776
Vitamin D signalling pathways in cancer: potential for anticancer therapeutics
Deeb, K. K., Trump, D. L., & Johnson, C. S. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2196 · Cited by 1,419
Self-citationVitamin D, disease and therapeutic opportunities
Plum, L. A., & DeLuca, H. F. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3318 · Cited by 477
Weekly High-Dose Calcitriol and Docetaxel in Metastatic Androgen-Independent Prostate Cancer
Beer, T. M., Eilers, K. M., Garzotto, M., Egorin, M. J., Lowe, B. A., & Henner, W. D. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.117 · Cited by 253
Metadata
- Authors
- Osborn, J. L., Schwartz, G. G., Smith, D. C., Bahnson, R., Day, R., & Trump, D. L.
- Venue
- Urologic Oncology: Seminars and Original Investigations
- Publisher
- Elsevier BV
- Published
- 1995-09
- Volume
- 1
- Issue
- 5
- Pages
- 195-198
- ISSN
- 1078-1439 (ISSN-L)
- OpenAlex
- W2006368250
- Cited by
- 170
- References
- 1
- FWCI
- 4.54
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer. https://app.cochat.ai/papers/10.1016/1078-1439(95)00061-5
- The paper
- Osborn, J. L., Schwartz, G. G., Smith, D. C., Bahnson, R., Day, R., & Trump, D. L. (1995). Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer. Urologic Oncology: Seminars and Original Investigations. https://doi.org/10.1016/1078-1439(95)00061-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.